Showing results (1521-1530 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|May 10, 2021
Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference GroupChantelle Murley, Petter Tinghög, Kristina Alexanderson, et al.
Pharmacoeconomics|July 27, 2025
Microsimulation Modeling for Health Decision Sciences Using C++: A TutorialAku-Ville Lehtimäki, Janne Martikainen
Pharmacoeconomics|December 3, 2025
Practical Considerations for Incorporating Equity More Explicitly in Australian Health Technology Assessment ProcessesAnagha Killedar, Martin Howell, Kirsten Howard, et al.
Pharmacoeconomics|December 31, 2024
A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and EvidenceBeth Woods, Alfredo Palacios, Mark Sculpher
Pharmacoeconomics|February 26, 2025
Making Composite Time Trade-Off Sensitive for Worse-than-Dead Health StatesMichał Jakubczyk, Bram Roudijk, Stefan A Lipman, et al.
Pharmacoeconomics|January 3, 2025
Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-EffectivenessOlena Mandrik, Chloe Thomas, Edifofon Akpan, et al.
Pharmacoeconomics|January 10, 2025
Prognostic Testing for Prostate Cancer-A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical PracticeAdam Fridhammar, Oskar Frisell, Karin Wahlberg, et al.
Pharmacoeconomics|September 2, 2024
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling StudyMeiyu Wu, Jing Ma, Sini Li, et al.
Pharmacoeconomics|August 24, 2024
Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory CommitteeZachary Tirrell, Alicia Norman, Martin Hoyle, et al.
Pharmacoeconomics|August 21, 2024
Drug Pricing Stewardship from Mark Cuban's Cost Plus Generic Drug ProgramSnigdha Gulati, Mohak Gupta, TingTing Yan, et al.
Pageof 336